×
For best experience we recommend to activate Javascript in your browser.
G-CSF antibody (AA 22-198)
This Mouse Monoclonal antibody specifically detects G-CSF in WB, IHC, IP and ICC. It exhibits reactivity toward Rat.
Quick Overview for G-CSF antibody (AA 22-198) (ABIN7614937)
Target
See all G-CSF (CSF3) Antibodies
G-CSF (CSF3)
(Colony Stimulating Factor 3 (Granulocyte) (CSF3))
Reactivity
All reactivities for G-CSF antibodies
Rat
Host
All hosts for G-CSF antibodies
Mouse
Clonality
All clonalities for G-CSF antibodies
Monoclonal
Conjugate
All conjugates for G-CSF antibodies
This G-CSF antibody is un-conjugated
Application
All applications for G-CSF antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Clone
C5
Product Details anti-G-CSF Antibody
(hide)
Binding Specificity
All epitopes for G-CSF antibodies
AA 22-198
Purpose
Colony Stimulating Factor 3, Granulocyte (GCSF) Monoclonal Antibody
Sequence
Ile22~Leu198
Characteristics
The Colony Stimulating Factor 3, Granulocyte (GCSF) Monoclonal Antibody (Species: Rat) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Protein A + Protein G affinity chromatography
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for G-CSF
(hide)
Target
G-CSF (CSF3)
(Colony Stimulating Factor 3 (Granulocyte) (CSF3))
Alternative Name
GCSF
UniProt
P97712
Pathways
Cellular Response to Molecule of Bacterial Origin , Regulation of Actin Filament Polymerization
Recently viewed
(hide)
Chat with us , powered by LiveChat